CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice

Home > Archive>Volume 17, Issue 7, 2009 >574-575

CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice
DOI:
                        
CSTR:
                        [cstr]
                    
Author:
                        
Affiliation:
Clc Number:
Fund Project:

Article

Figures

Metrics

Reference

Cited by

Materials

Comments

Abstract:

Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.

Reference

Cited by

Get Citation

Willeke de Haan, Jitske de Vries-van der Weij, Caroline C. van der Hoogt, José W. A. van der Hoorn, Johannes A. Romijn, J. Wouter Jukema, Louis M. Havekes, Hans M. G. Princen, Patrick C. N. Rensen. CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2009,17(7):574-575.

Copy

Article Metrics

Abstract:
PDF:
HTML:
Cited by:

History

Received:
Revised:
Adopted:
Online:
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code